We have finally come to the end of ESMO 2024, and as is now tradition, Michael and Josh conclude their epic journey with a special episode highlighting their absolute favourite practice-changing selections from the Plenary Sessions. As always, ESMO brought a selection of wonderful studies that truly deserve the title "practice changing." As always, a huge thanks to everyone who joined us on this amazing journey. It has been a wonderful experience to attend a major international conference for the first time, and we are so privileged to be able to bring these results to you.

Stay tuned to Oncology for the Inquisitive Mind in the coming weeks as we will be starting our ESMO 2024: Retrospective miniseries, where we speak to experts in the areas of breast, lung, GI, GU and skin cancers and get their opinions on the goings on in Barcelona.

PEACE-3

PODIUM

KEYNOTE-A18

KEYNOTE-522 OS Data

NIAGRA

Note: this episode was recorded over two days at two separate locations.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.

The end of the road approaches, and ESMO 2024 will soon be in the rear view mirror. However, each new day brings new, incredible advances in the treatment of cancer. Today, Josh and Michael dive into biomarker analyses, overall survival updates and new antibody-drug conjugates galore. Listen on for our penultimate summary of ESMO.

Studies discussed in this episode:

Biomarker analysis of PEACE-1

ARANOTE

STAMPEDE - Addition of Metformin

Clinical activity of BMS-986365, dual androgen receptor ligand-directed degrader and antagonist in heavily pretreated mCRPC

Nivo (3mg/kg) + ipi (1mg/kg) in molecularly-selected patients with mCRPC

Neoadjuvant nivo/rela or nivo/ipi in TNBC with high TILs

Adjuvant ribo + NSAI in patients with HR+/HER2- EBC: 4 year NATALEE

Cabozantinib vs placebo for advanced NET after progression on prior therapy (CABINET)

Osimertinib after definitive CRT: analysis of CNS and distant progression from LAURA

POTENTIAL

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Spotify Link to Prof Joshua's podcast, Dangerous Ideas in Drug Development: https://podcasters.spotify.com/pod/show/necta

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Splash

Disitimab Vedotin

Hosted on Acast. See acast.com/privacy for more information.

Day three of the European Society of Medical Oncology Congress had many exciting and potentially practice-changing trials in the genitourinary space. Gone are the days of urothelial cancer having a single treatment and prostate cancer only having androgen deprivation therapy.

They look at biomarkers for ADC response in bladder cancer, the use of lutetium upfront for metastatic hormone-sensitive prostate cancer, and novel ADC use in metastatic urothelial carcinoma.

Links to studies discussed in this episode (subscription may be required):

DV001 (Disitamab vedotin (DV) + pembrolizumab in treatment-naïve HER2-expressing LA/met UC)

EV-302 - nectin four expression

UpFrontPSMA Study

Splash Study (Lu-PNT2002)

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.com

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Splash

Disitimab Vedotin

Hosted on Acast. See acast.com/privacy for more information.